EML4-ALK Fusion Gene Detection Kit
PCR
Real-time PCR Assays
100%
100%
Specificity
100%
100%
Accuracy
25 copies/μL
Sensitivity
Features
Selectable
- Pre-loaded and bulk formats are available.
1
- Pre-loaded and bulk formats are available.
Universal
- Compatible with tissue samples.
2
- Compatible with tissue samples.
Precise
- Top sensitivity of 25 copies/rxn.
3
- Top sensitivity of 25 copies/rxn.
Easy
- Two steps procedure, results in 150 mins.
4
- Two steps procedure, results in 150 mins.
Reliable
- External control included.
5
- External control included.
Product Description

EML4-ALK Fusion Gene Detection Kit

The anaplastic lymphoma kinase (ALK) gene is frequently involved in rearrangements that lead to gene fusions in lung cancer. Fusion partner of echinoderm microtubule-associated protein-like 4 (EML4) is frequently found in non-small-cell lung cancer (NSCLC). The recombinant EML4-ALK activates the receptor tyrosine kinase's downstream signaling pathway, which includes PI3K/AKT, leading to carcinogenesis. It has been reported that the presence of the EML4-ALK fusion is correlated with the efficacy of 4LK-targeted therapy. Based on analysis of tumor messenger RNA, EML4-ALK fusions can be detected by real-time PCR method.

Intended Use

AmoyDx® EML4-ALK Fusion Gene Detection Kit is a real-time PCR assay for qualitative detection of 21 EML4-ALK fusions in total RNA extracted from formalin-fixed paraffin-embedded (FFPE) tumor tissue in NSCLC patients.

The kit is for research use only, and intended to be used by trained professionals in a laboratory environment.

Testing Procedure
Compatible Sample Types:FFPE Samples
Compatible Real-time PCR Instrument
ABI 7500
Bio-Rad CFX96
LightCycler 480 II
Rotor-Gene Q
Rotor-Gene 6000
SLAN-96S
Stratagene Mx3000P™
Other Info.

To order, please contact sales@amoydx.com.

 Product Name

Size (tests/kit) 

Storage 

 EML4-ALK Fusion Gene Detection Kit (Bulk)

 24T

 -20 ℃


Publications
1. Cai, Weijing, et al. "Intratumoral heterogeneity of ALK-rearranged and ALK/EGFR coaltered lung adenocarcinoma." Journal of clinical oncology 33.32 (2015): 3701.
2. Ying, J., et al. "Diagnostic value of a novel fully automated immunochemistry assay for detection of ALK rearrangement in primary lung adenocarcinoma." Annals of oncology 24.10 (2013): 2589-2593.
3. Shan, Ling, et al. "Combination of conventional immunohistochemistry and qRT-PCR to detect ALK rearrangement." Diagnostic pathology 9.1 (2014): 3.
4. Hou, Likun, et al. "High concordance of ALK rearrangement between primary tumor and paired metastatic lymph node in patients with lung adenocarcinoma." Journal of thoracic disease 8.6 (2016): 1103.
5. Tuononen, Katja, et al. "Targeted resequencing reveals ALK fusions in non-small cell lung carcinomas detected by FISH, immunohistochemistry, and real-time RT-PCR: a comparison of four methods." BioMed research international 2013 (2013).
6. Incharoen, Pimpin, et al. "ALK-rearranged pulmonary adenocarcinoma in Thai Patients: From diagnosis to treatment efficacy." World journal of surgical oncology 14.1 (2016): 139.
7. Nakamichi, Shinji, et al. "RT-PCR for detecting ALK translocations in cytology samples from lung cancer patients." Anticancer research 37.6 (2017): 3295-3299.
8. Mikes, Romana E., et al. "First line crizotinib in anaplastic lymphoma kinase (ALK) rearranged squamous cell lung cancer." Lung Cancer 90.3 (2015): 614-616.

Certificate
BACK
Inquiry
Inquiry
* Required information
Manage your account info
Change your password